Evidence map›Paper›PMID 41190572›Full record

ReviewACS chemical neuroscience2025

Simple Analogs of the LSD D-Ring: A Consideration of Structure-Activity Relationships and Their Potential as Therapeutics.

Steven A Barker

Abstract readReview
In one paragraph

Review in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Deconstruction of lysergic acid diethylamide.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Steven A BarkerDepartment of Comparative Biomedical Sciences, Louisiana State University, Baton Rouge, Louisiana 70803, United States.ORCID 0000-0002-5755-3496

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psychedelic drugs have begun to show therapeutic promise. However, there is a growing research effort focused on creating nonhallucinogenic analogs of these substances. The goal is to develop new treatments for an expanding list of psychiatric and neurodegenerative disorders, while eliminating the complications and costs of treatment engendered by the subjective psychedelic experience. Structure-activity relationships (SAR), particularly for LSD (d-lysergic acid diethylamide), have guided many of these efforts. This perspective examines the historical development and behavioral testing of several simple analogs of LSD's D-ring, which, while nonhallucinogenic and nontoxic within the context of their testing to date, can block the behavior-disrupting effects of psychedelics administered to rodents. However, these data are quite mature. D-ring analogs of LSD may have therapeutic potential but require further testing to examine binding, plastogenic effects, and potential utility in psychiatry and neuromedicine, and are ripe for reinvestigation with current tools, approaches, and concepts. Further, the SAR data strongly suggest that the incorporation of several changes to the structural elements of the D-ring may enhance the effects of other LSD-related analogs currently undergoing clinical trials.

Indexed as

HallucinogensLysergic Acid DiethylamideAnimalsHumansStructure-Activity RelationshipHallucinogensLysergic Acid DiethylamideD-ringLSDnonhallucinogenicpsychedelicstructure−activity relationships (SAR)therapeutics

Identifiers

PMID41190572
PMCPMC12636032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.